EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, WAVE Life Sciences's enterprise value is $416.3 Mil.
WAVE Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-58.8 Mil. Therefore, WAVE Life Sciences's EV-to-EBITDA for today is -7.08.
The historical rank and industry rank for WAVE Life Sciences's EV-to-EBITDA or its related term are showing as below:
WVE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.25 Med: -3.64 Max: 0.08
Current: -7.08
During the past 11 years, the highest EV-to-EBITDA of WAVE Life Sciences was 0.08. The lowest was -19.25. And the median was -3.64.
WVE's EV-to-EBITDA is ranked worse than 100% of 469
companies
in the Biotechnology industry
Industry Median: 9.16
vs WVE: -7.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), WAVE Life Sciences's stock price is $4.80.
WAVE Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.550. Therefore, WAVE Life Sciences's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
WAVE Life Sciences EV-to-EBITDA Historical Data
The historical data trend for WAVE Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
WAVE Life Sciences Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-0.81
-1.59
-0.57
-3.65
-7.37
WAVE Life Sciences Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-3.65
-1.75
-1.75
-5.55
-7.37
Competitive Comparison
For the Biotechnology subindustry, WAVE Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's EV-to-EBITDA falls into.
WAVE Life Sciences EV-to-EBITDA Calculation
WAVE Life Sciences's EV-to-EBITDA for today is calculated as:
WAVE Life Sciences's current Enterprise Value is $416.3 Mil.
WAVE Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (NAS:WVE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
WAVE Life Sciences's PE Ratio for today is calculated as:
WAVE Life Sciences's share price for today is $4.80.
WAVE Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of WAVE Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences (WAVE Life Sciences) Business Description
WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 